Tamoxifen and EGCG Combination Reduces Breast Cancer Growth
Author Information
Author(s): Scandlyn M J, Stuart E C, Somers-Edgar T J, Menzies A R, Rosengren R J
Primary Institution: Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand
Hypothesis
The combination of tamoxifen and epigallocatechin gallate (EGCG) will significantly suppress tumor growth in ER-negative breast cancer.
Conclusion
The combination of tamoxifen and EGCG significantly reduced tumor growth in ER-negative breast cancer models.
Supporting Evidence
- Tamoxifen and EGCG together reduced tumor volume by 71% compared to control.
- Tamoxifen alone was not effective in suppressing ER-negative tumor growth.
- EGCG treatment did not change ER protein expression in MDA-MB-231 cells.
Takeaway
Giving mice a mix of two drugs, tamoxifen and EGCG, helped stop the growth of a type of breast cancer that usually doesn't respond to tamoxifen alone.
Methodology
Athymic nude female mice were implanted with MDA-MB-231 cells and treated with tamoxifen, EGCG, or their combination for 10 weeks.
Limitations
The study was conducted in a mouse model, which may not fully replicate human responses.
Participant Demographics
Female CD1 athymic nude mice, 5- to 6-week old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website